Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified.
In a randomized clinical trial (MAP study), the prophylactic efficacy of lithium and carbamazepine was compared in a subgroup of patients (n = 57) who presented either a bipolar II disorder or a bipolar disorder not otherwise specified (DSM-IV). During the observation period of 2.5 years, no significant differences between the drugs were found considering hospitalization, recurrences, subclinical recurrences, concomitant medication and severe side-effects.
Greil
W
W
Psychiatric Hospital, University of Munich, Germany. wgreil@psy.med.uni-muenchen.de
Kleindienst
N
N
D000328:Adult; D018692:Antimanic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D002220:Carbamazepine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
D018692:Antimanic Agents; D016651:Lithium Carbonate; D002220:Carbamazepine